EUCTR2004-000822-58-GB进行中（未招募）1 期
Clopidogrel and Acetyl salicylic acid in bypass Surgery for Peripheral ARterial disease. A double blind randomised study of clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft - CASPAR 2004
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,460
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A patient is eligible for inclusion in the study 2-4 days after surgery if all the following criteria are fulfilled:
- •- Informed consent obtained;
- •- Patient aged >= 40 years and <= 80 years;
- •- Chronic background treatment with daily ASA or Triflusal, whatever the dose, started at least 4 weeks before surgery.
- •A window of a few days without ASA or Triflusal before surgery is acceptable, according to local practice. Post- randomization dose of ASA must be between 75 and 100 mg/day.
- •- Unilateral below knee bypass graft (i.e. the distal anastomosis is below the level of the knee joint) for atherosclerotic PAD within the previous 4 days;
- •-Demonstration of initial patency of the index graft by an objective measurement (e.g. intra-operative Doppler scanning, flow measurement, angiography, Duplex scanning) during bypass surgery, or between surgery and the time of randomization;
- •-No clinical evidence of graft occlusion at time of randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients having any of the following at randomization will not be included in the study:
- •?PAD medical/surgical history
- •-Onset of PAD symptoms before the age of 40 years
- •-Non-atherosclerotic vascular disease (e.g. Buerger’s disease, popliteal entrapment syndrome)
- •-Patients undergoing, along with the below knee bypass any other surgical intervention (or who has undergone one within the last four weeks before surgery), except endovascular procedures of the opposite leg at the femoral level or below (cf note below).
- •- Any aneurysm in or near the operated segment
- •?Medical history related to bleeding risk
- •-Current active bleeding at surgical site
- •-Withdrawal of an epidural catheter less than 12 hours before randomization
- •-Current active bleeding or increased risk of bleeding, such as severe hepatic insufficiency, proliferative diabetic retinopathy, peptic ulceration, bleeding diathesis or coagulopathy
- •-Peptic ulceration within 12 months of randomization
- •-Previous or current intracranial hemorrhage or hemorrhagic stroke, or any previous stroke for which the diagnosis of hemorrhagic stroke cannot be excluded
- •-Any history of severe spontaneous bleeding such as gastrointestinal bleeding, gross hematuria, intraocular bleeding.
- •?Other medical conditions
- •-Previous disabling stroke (severe cerebral deficit such that the patient is bedridden or demented)
- •-NYHA Class IV heart failure
- •-Uncontrolled hypertension: Systolic Blood Pressure (SBP) > 180 mm Hg, or Diastolic Blood Pressure (DBP) > 100 mm Hg
- •-High probability of death of non-cardiovascular cause, within the next 12 months.
- •-History of clinically significant or persistent thrombocytopenia or current platelet count less than 120 G/L
- •-History of clinically significant or persistent neutropenia or current neutrophil count less than 1.8 G/L
- •-Pregnant women, or women of childbearing potential who are not following an effective method of contraception.
- •?Recent or planned medical therapy
- •-Thrombolytic therapy within 24 hours prior to randomization, or use of GPIIb/IIIa receptor antagonist within 4 days prior to randomization
- •-Hypersensitivity to the drug substance or any component of the product
- •-Associated condition requiring chronic use of oral anticoagulants (e.g. warfarin, ximelagatran) or antiplatelet agents (including dipyridamole, cilostazol, GPIIb/IIIa antagonists, ticlopidine, clopidogrel or ASA>100mg/d)
- •?Other exclusion criteria
- •-Simultaneous or previous participation (in the 30 days prior to study entry) in a clinical study using an experimental drug or device
- •-Prior enrolment in this trial
- •-Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study, or language barrier such that the subject is unable to give informed consent
- •-Uncooperative attitude or potential for non-compliance with the requirements of the protocol making study participation impractical.
- •1) Only patients with unilateral be
研究者
相似试验
已完成
不适用
Effect of clopidogrel and acetylsalicylic acid (ASA) versus clopidogrel or ASA alone on brachial flow mediated vasodilation in patients with coronary artery diseaseStable coronary artery diseaseCirculatory SystemChronic ischaemic heart diseaseISRCTN34097747Johannes Gutenberg-University Mainz (Johannes Gutenberg-Universitat Mainz) (Germany)120
已完成
不适用
Evauation of usefulness of clopidogrel bisulfate against ischemic cerebrovascular disordersacunar strokeJPRN-UMIN000006870Masafumi Ihara30
尚未招募
4 期
Do new blood-thinning treatments commenced after cardiac surgery keep By-Pass Grafts open longer ?Coronary Artery Graft Patency following Coronary Artery Bypass Graft (CABG) post Acute Coronary Syndrome (ACS)Cardiovascular - Coronary heart diseaseSurgery - Other surgeryACTRN12613001362785Waikato District Health Board400
进行中（未招募）
1 期
The use of clopidogrel and aprotonin in off pump coronary artery bypass graftingBleeding after coronary artery bypass graftingMedDRA version: 9.1 Level: LLT Classification code 10005645 Term: Blood loss of (NOS)EUCTR2007-002652-42-GBRoyal Brompton and Harefield NHS Trsut270
进行中（未招募）
不适用
International Study using Clopidogrel and Aspirin for the treatment of Polycythemia Vera. - ISCLAPMedDRA version: 9.1Level: LLTClassification code 10036057Term: Polycythaemia veraPolycythemia VeraEUCTR2007-007801-63-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI